Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 23

1.

Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.

Benditt DG, Williams JH, Jin J, Deering TF, Zucker R, Browne K, Chang-Sing P, Singh BN.

Am J Cardiol. 1999 Aug 1;84(3):270-7.

PMID:
10496434
2.

Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation.

Southworth MR, Zarembski D, Viana M, Bauman J.

Am J Cardiol. 1999 Jun 15;83(12):1629-32.

PMID:
10392866
3.

Low-dose amiodarone versus sotalol for suppression of recurrent symptomatic atrial fibrillation.

Kochiadakis GE, Igoumenidis NE, Marketou ME, Solomou MC, Kanoupakis EM, Vardas PE.

Am J Cardiol. 1998 Apr 15;81(8):995-8.

PMID:
9576159
4.

Adverse effects of amiodarone.

Jafari-Fesharaki M, Scheinman MM.

Pacing Clin Electrophysiol. 1998 Jan;21(1 Pt 1):108-20. Review.

PMID:
9474655
5.

Effects of amiodarone on thyroid function.

Harjai KJ, Licata AA.

Ann Intern Med. 1997 Jan 1;126(1):63-73. Review.

PMID:
8992925
6.

Clinical challenge. I: Control of recurrent symptomatic atrial fibrillation.

Reimold SC.

Eur Heart J. 1996 Jul;17 Suppl C:35-40. Review.

PMID:
8809537
8.

Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association.

Prystowsky EN, Benson DW Jr, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG.

Circulation. 1996 Mar 15;93(6):1262-77. Review. No abstract available.

9.

Recurrence of paroxysmal atrial fibrillation or flutter after successful cardioversion in patients with normal left ventricular function.

Suttorp MJ, Kingma JH, Koomen EM, van 't Hof A, Tijssen JG, Lie KI.

Am J Cardiol. 1993 Mar 15;71(8):710-3.

PMID:
8447270
10.

Comparative mechanisms of antiarrhythmic drug action in experimental atrial fibrillation. Importance of use-dependent effects on refractoriness.

Wang J, Bourne GW, Wang Z, Villemaire C, Talajic M, Nattel S.

Circulation. 1993 Sep;88(3):1030-44.

PMID:
8353865
11.

Class III antiarrhythmic drugs.

Singh BN, Ahmed R.

Curr Opin Cardiol. 1994 Jan;9(1):12-22. Review.

PMID:
8199363
12.

Comparison of class I and class III action in atrial fibrillation.

Edvardsson N.

Eur Heart J. 1993 Nov;14 Suppl H:62-6. Review.

PMID:
7904938
13.

Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter.

Chun SH, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN.

Am J Cardiol. 1995 Jul 1;76(1):47-50.

PMID:
7793402
14.

Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group.

Scheinman MM, Levine JH, Cannom DS, Friehling T, Kopelman HA, Chilson DA, Platia EV, Wilber DJ, Kowey PR.

Circulation. 1995 Dec 1;92(11):3264-72.

15.

Newer developments in the management of atrial fibrillation.

Nattel S.

Am Heart J. 1995 Nov;130(5):1094-106. Review.

PMID:
7484742
16.

Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity.

Rotmensch HH, Belhassen B, Swanson BN, Shoshani D, Spielman SR, Greenspon AJ, Greenspan AM, Vlasses PH, Horowitz LN.

Ann Intern Med. 1984 Oct;101(4):462-9.

PMID:
6476633
17.

Amiodarone for refractory atrial fibrillation.

Gold RL, Haffajee CI, Charos G, Sloan K, Baker S, Alpert JS.

Am J Cardiol. 1986 Jan 1;57(1):124-7.

PMID:
3942054
18.

Transtelephonic electrocardiographic transmission for management of cardiac arrhythmias.

Antman EM, Ludmer PL, McGowan N, Bosak M, Friedman PL.

Am J Cardiol. 1986 Nov 1;58(10):1021-4.

PMID:
3776841
19.

Therapeutic efficacy and safety of oral propafenone for atrial fibrillation.

Porterfield JG, Porterfield LM.

Am J Cardiol. 1989 Jan 1;63(1):114-6. No abstract available.

PMID:
2909141
20.

Therapy of refractory symptomatic atrial fibrillation and atrial flutter: a staged care approach with new antiarrhythmic drugs.

Antman EM, Beamer AD, Cantillon C, McGowan N, Friedman PL.

J Am Coll Cardiol. 1990 Mar 1;15(3):698-707.

Supplemental Content

Support Center